Oramed Pharmaceuticals Financials - Benzinga

Oramed Pharmaceuticals Inc

ORMPNASDAQ

Trade with Public

Trade with Public

$4.85

-0.17-3.39%

At close: Sep 1, 5:00 PM EST

$5.01

0.163.3%

After Hours: 9:30 AM EST

Overview News Earnings Forecast Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Oramed Pharmaceuticals Financials

Oramed Pharmaceuticals (ORMP) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Reported November 13, 2025: Oramed Pharmaceuticals Q3 EPS $1.26 Beats $(0.08) Estimate, Sales $2.000M

Oramed Pharmaceuticals (NASDAQ:ORMP) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $(0.08) by 1675 percent. This is a 672.73 percent increase over losses of $(0.22) per share

Benzinga Newsdesk

Dow Tumbles 250 Points; CarMax Posts Upbeat Results

U.S. stocks traded lower this morning, with the Dow Jones dropping around 250 points on Friday. Following the market opening Friday, the Dow traded down 0.74% to 33,695.28 while the NASDAQ fell 0.98% to 13,497.22. The S&P 500, also fell, dropping, 0.78% to 4,347.58.

Lisa Levin

Gold Tops $1,900 After US CPI Report, S&P 500 Rises 0.5%

U.S. stocks traded higher toward the end of trading, following the release of inflation data.

Lisa Levin

US Stocks Turn Higher; Dow Jumps 200 Points

U.S. stocks turned higher midway through trading, following the release of inflation data.

Lisa Levin

Dow Drops 150 Points; US Inflation Rate Slows In December

U.S. stocks traded lower this morning, following the release of inflation data.

Lisa Levin

Looking Into Oramed Pharmaceuticals's Return On Capital Employed

Benzinga Insights